Hulk Hogan, wrestling icon, dies at 71 in Florida home
TOKYO and NEW YORK - Astellas Pharma Inc. (TSE: 4503), a $17.3 billion market cap pharmaceutical company with impressive 19.25% revenue growth, and Pfizer Inc. (NYSE: PFE) have announced results from the five-year follow-up of the Phase 3 ARCHES trial, indicating that XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces the risk of death by 30% in men with metastatic hormone-sensitive prostate cancer (mHSPC). According to InvestingPro analysis, Astellas maintains a strong financial health rating of GOOD, with an industry-leading gross profit margin of 81.74%. The study found a 66% probability of survival at five years with XTANDI plus ADT versus a 53% probability with placebo plus ADT.
The ARCHES trial, which enrolled 1,150 patients globally, has demonstrated the long-term efficacy of XTANDI in various patient subgroups, particularly those with high-volume disease, no prior docetaxel use, and synchronous disease. The safety profile over the five-year period was consistent with previous analyses, with no new safety concerns identified. With last twelve months revenue reaching $12.75 billion, Astellas appears undervalued according to InvestingPro’s Fair Value analysis, suggesting potential upside for investors tracking pharmaceutical developments.
Dr. Andrew J. Armstrong from the Duke Cancer Institute highlighted the significance of the results, stating that two-thirds of men are now surviving five years, marking a substantial improvement over standard hormonal therapy alone. XTANDI is now considered a standard of care for mHSPC, changing the trajectory for patients living with the disease. For deeper insights into Astellas’s financial health and growth prospects, including 12+ exclusive ProTips, visit InvestingPro.
Further supporting XTANDI’s efficacy, eight-year data from the independent ENZAMET study, sponsored by the University of Sydney, will also be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. The ENZAMET study observed a reduction in the risk of death in men with mHSPC when treated with XTANDI plus testosterone suppression compared to non-steroidal anti-androgen (NSAA) plus testosterone suppression.
XTANDI is approved in over 90 countries and has treated over one million patients globally since its initial approval in 2012. The results from the ARCHES study will be submitted for publication in a peer-reviewed journal.
The information in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.